AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8730606
Drug: 320 ml
RxNorm normalized name: PYRITHIONE ZINC 6.4 g in 320 mL TOPICAL SHAMPOO [HAIRJOY MSM HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 ml of dealcoholised red wine
Trial: 1523877
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (12.5 ng)
Trial: 1523877
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (25 ng)
Trial: 1523877
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (6.3-25 ng)
Trial: 1523877
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (12.5 ng and 25 ng)
Trial: 1335640
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine
Trial: 28855226
Drug: Antibiotic (cephalexin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic (cephalexin if <6 months or co-trimoxazole if >6 months old) administered a day prior to VCUG and continued for 1 day post VCUG
Trial: 19080672
Drug: oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral metronidazole sustained release tablet 750 mg/day for 7 days and vaginal tinidazole 250 mg for 7 days
Trial: 19080672
Drug: oral tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tinidazole 1 g/day for 3 days (2 g for the first dose)
Trial: 19080672
Drug: oral ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ornidazole 2 x 500 mg/day for 3 days and vaginal tinidazole 250 mg for 7 days
Trial: 19080672
Drug: oral ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ornidazole 2 x 500 mg/day for 3 days
Trial: 19080672
Drug: oral secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral secnidazole 2 g in a single dose and vaginal tinidazole 250 mg for 7 days
Trial: 9722127
Drug: oral secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral secnidazole 2 g in a single dose
Trial: 7965311
Drug: Postoperative instructions
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative instructions with descriptive information regarding potential sequelae and analgesic use
Trial: 3309236
Drug: Inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin (100 mg twice a day) as adjunct to intravenous ceftazidime (250 mg/kg/day) and amikacin (33 mg/kg/day)
Trial: 3309236
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy only (ceftazidime 250 mg/kg/day and amikacin 33 mg/kg/day)
Trial: 3309236
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (inhaled amikacin and intravenous therapy)
Trial: 16817045
Drug: Initial medical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medical treatment
Trial: 2565266
Drug: Ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine plus bromazepam (300 mg ranitidine and 6 mg bromazepam)
Trial: 2565266
Drug: Ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine plus placebo (300 mg ranitidine and placebo)
Trial: 28421246
Drug: Intravenous polyspecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polyspecific immunoglobulin G (IVIG) 25 g once daily for the first 3 days
Trial: 28421246
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline) equal volume once daily for the first 3 days
Trial: 19337810
Drug: Intraarticular hyaluronate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronate injection
Trial: 16924992
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop (APL, 3M ESPE)
Trial: 11213852
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of citalopram 40 mg plus placebo
Trial: 11213852
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ketoconazole 200 mg plus single dose of citalopram 40 mg
Trial: 31158560
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) plus standardised medical care
Trial: 19268383
Drug: Continual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continual insulin injection
Trial: 19268383
Drug: Continual secretagogue
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continual secretagogue administration
Trial: 16854236
Drug: Unsupervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised treatment with artemether-lumefantrine (A/L)
Trial: 12700619
Drug: Multi‐micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi‐micronutrient supplementation (3.5 g/l)
Trial: 9876348
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg i.v.)
Trial: 30982443
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (300,000 IU, single muscular injection)
Trial: 30982443
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 ml, Placebo group)
Trial: 23375496
Drug: Dexamethasone 0.4
RxNorm normalized name: dexamethasone 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.4 mg/kg preoperatively
Trial: 17010635
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution at 20 degrees C
Trial: 17010635
Drug: Topical papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical papaverine at 20 degrees C
Trial: 17010635
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution at 37 degrees C
Trial: 15543714
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene 0.1% gel or cream once daily for 12 weeks
Trial: 15543714
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene cream formulation
Trial: 15543714
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene gel formulation
Trial: 11758661
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment package
Trial: 18046975
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg once daily
Trial: 9156363
Drug: Felodipine extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended‐release 5-10 mg once daily
Trial: 26411504
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) containing 90 µg I with 0 or 10 mg Zn, 20 g/day from 9 to 18 months of age.
Trial: 21410297
Drug: Orally dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally dosed non-(14)C-labeled lesogaberan (100 mg)
Trial: 16448895
Drug: candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan 8 to 16 mg
Trial: 12562705
Drug: Tablets 500/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets 500/125 mg
Trial: 12562705
Drug: Tablets 875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets 875/125 mg
Trial: 12562705
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension 250/62.5 mg per 5 mL
Trial: 11524325
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine injection
Trial: 9007884
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no epidural morphine)
Trial: 8513309
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Trial: 8513309
Drug: Potassium-Canrenoate (K-Can)
RxNorm normalized name: potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-Canrenoate (K-Can) 50 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Trial: 8513309
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (HCTZ and K-Can)
Trial: 2872804
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 to 40 mg once daily)
Trial: 28926353
Drug: Lacosamide 200
RxNorm normalized name: lacosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 200 mg
Trial: 17120972
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose Vi polysaccharide vaccine (Typherix)
Trial: 17120972
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control hepatitis A vaccine (Havrix)
Trial: 11275505
Drug: General practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practice methadone maintenance treatment
Trial: 9284777
Drug: hPTH [1-34],
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH [1-34], 400 U/25 micrograms daily subcutaneously
Trial: 9284777
Drug: Hormone-replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone-replacement therapy only (Control)
Trial: 27511844
Drug: Cetux‐FHX (cetuximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetux‐FHX (cetuximab, 5‐fluorouracil, hydroxyurea, and 1.5 Gy twice‐daily radiation therapy every other week to 75 Gy)
Trial: 27511844
Drug: Cetux‐PX (cetuximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetux‐PX (cetuximab, cisplatin, and accelerated radiation therapy with delayed concomitant boost to 72 Gy in 42 fractions)
Trial: 17226852
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy in children on concomitant corticosteroids
Trial: 10405232
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy using lansoprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Trial: 10405232
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy using omeprazole or lansoprazole plus clarithromycin and amoxicillin
Trial: 7562290
Drug: Lactose-glucose polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-glucose polymer combination
Trial: 7562290
Drug: Lactose-glucose polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-glucose polymer combination and glucose polymers alone
Trial: 1536959
Drug: rhGM‐CSF (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF (8 micrograms glycoprotein (5.5 micrograms protein)/kg/d, continuous IV infusion for 14 days)
Trial: 6509876
Drug: Prompt phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prompt phenytoin sodium capsules (divided doses)
Trial: 6509876
Drug: Prompt phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prompt phenytoin sodium capsules (single doses)
Trial: 6509876
Drug: Phenytoin sodium
RxNorm normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin sodium injection
Trial: 19575366
Drug: 1.5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 microg/kg peginterferon alfa-2b weekly plus 800-1,400 mg ribavirin daily for 48 weeks (group A)
Trial: 19575366
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored treatment duration (18-48 weeks; group B)
Trial: 30352838
Drug: Tamoxifen 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 5 mg daily
Trial: 12123540
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily
Trial: 11759825
Drug: Tamoxifen (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (all doses)
Trial: 11199932
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg starting dose for 12 weeks or 25 mg starting dose for 10 weeks)
Trial: 9753259
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every morning
Trial: 3065016
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Trial: 3065016
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Trial: 26302441
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone
Trial: 30148731
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-test kits and HIV testing information (study arm 3)
Trial: 30148731
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-test kits
Trial: 16428249
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks
Trial: 9678123
Drug: Low-dose monophasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monophasic combined oral contraceptive (100 micrograms levonorgestrel/20 micrograms ethinylestradiol)
Trial: 31675102
Drug: All fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All fremanezumab groups (quarterly and monthly combined)
Trial: 27385305
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no systemic therapy)
Trial: 10434812
Drug: Midazolam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3 mg kg‐1 followed by 0.15 mg kg‐1 h‐1)
Trial: 10434812
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg kg‐1 followed by 10‐6 mg kg‐1 h‐1)
Trial: 205633
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol treatment
Trial: 205633
Drug: Chlordiazepoxide treatment
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide treatment
Trial: 16412857
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin (ATV)
Trial: 8378661
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg q.p.m. initially, increased to 40 mg q.p.m. for 64% of patients after 18 weeks)
Trial: 8378661
Drug: Gemfibrozil (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (900 mg q.p.m.)
Trial: 3796783
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein intake (0.4 g/kg/day) supplemented with keto analogues of essential amino acids
Trial: 3796783
Drug: Standard low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard low protein diet (0.6 g/kg/day)
Trial: 26935962
Drug: Extraction group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction group (multiband treatment plus isolated extraction of mandibular teeth)
Trial: 22644342
Drug: AST-120 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 2 g administered simultaneously with triazolam 0.25 mg
Trial: 7750306
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP), 400 micrograms, two times daily
Trial: 2248822
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with adrenaline 5 micrograms ml‐1
Trial: 7028536
Drug: Acipimox 150
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 150 mg
Trial: 8444273
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg
Trial: 28108059
Drug: Cognitive‐Behavioral Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Group Therapy (CBGT)
Trial: 21352660
Drug: Nebulized bronchodilator
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized bronchodilator + oxygen + forward‐leaning posture
Trial: 17355549
Drug: Active preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active preparation (cannabis-based medicine containing THC and CBD)
Trial: 15566533
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of patient records for SP visits
Trial: 11572286
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B 40
Trial: 10622084
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin 50 IU
Trial: 10622084
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin 100 IU
Trial: 9541513
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin 200 IU
Trial: 10331733
Drug: Rifapentine 300
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 300 mg daily
Trial: 30670438
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg daily
Trial: 10331733
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg every 3 days
Trial: 1674842
Drug: Syrup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup of ipecac (SOI) before activated charcoal (AC)
Trial: 7007060
Drug: Clonidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.4 +/- 0.15 mg/day)
Trial: 31768697
Drug: PF-06439535 plus
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06439535 plus chemotherapy
Trial: 31768697
Drug: bevacizumab-EU plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab-EU plus chemotherapy
Trial: 30988146
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg, intravenously/orally, twice daily for 10 days
Trial: 11961019
Drug: Modified peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified peritoneal dialysis prescription to achieve a peritoneal creatinine clearance (pCrCl) of 60 L/wk per 1.73 m(2)
Trial: 27904912
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 3 sessions, each one week apart, 2,000 rESWT impulses per session, positive energy flux density 0.10-0.16 mJ/mm2
Trial: 26008634
Drug: β‐alanine (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐alanine (3.2 g/day)
Trial: 10770191
Drug: IGF‐I/IGFBP‐3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I/IGFBP‐3 (2 mg/kg‐day) by continuous sc infusion for 2 weeks